A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

Conditions: Healthy Interventions: Drug: Caffeine Tablet; Drug: Omeprazole capsule; Drug: Warfarin tablet; Drug: LOXO-305 Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials